Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

December 04, 2018; 91 (23 Supplement 1) Abstracts

Cannabis, concussion, and chronic pain: An ongoing retrospective analysis at Dent Neurologic Institute in Buffalo, NY

Jennifer McVige, Vincent Harry Bargnes, Said Shukri, Laszlo Mechtler
First published December 5, 2018, DOI: https://doi.org/10.1212/01.wnl.0000550692.23055.1f
Jennifer McVige
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Harry Bargnes III
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Said Shukri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laszlo Mechtler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Cannabis, concussion, and chronic pain: An ongoing retrospective analysis at Dent Neurologic Institute in Buffalo, NY
Jennifer McVige, Vincent Harry Bargnes, Said Shukri, Laszlo Mechtler
Neurology Dec 2018, 91 (23 Supplement 1) S18-S19; DOI: 10.1212/01.wnl.0000550692.23055.1f

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
721

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective To examine medical cannabis (MC) as treatment for concussion-related chronic pain.

Design/methods Individuals with concussion often experience chronic discomfort from headaches. MC treatment was approved for use in chronic pain by New York State in March 2017. DENT has treated 4,123 patients with MC, including 2,792 for chronic pain and 142 with concussion symptoms. Sixty-six charts were reviewed, with a total of 100 expected by presentation.

Preliminary results (1) The Patient Global Impression of Improvement (PGI-I) scale revealed 80% of patients experienced significant improvement in activity level and symptoms. (2) Five common concussion symptoms (headache, mood, sleep, attention, and dizziness) were evaluated via modified-Likert scale (0 rated as “Much Worse” and 10 as “Much Better”). Moderate improvement (MI) was defined as 7–8 and significant improvement (SI) 9–10. Improvement was greatest in mood (63% MI, 20% SI), sleep (53% MI, 23% SI), and headache (60% MI, 14% SI). (3) Quality of Life after Brain Injury Score (QOLIBRI) scores were obtained on patients who had started MC (46) and those who had not yet (19). Comparison of the groups showed a significant improvement (p = 0.0035) in quality of life in individuals on MC. (4) The routes of administration that produced optimal benefit were 1:1 (THC:CBD) oral tincture at an average dose of 1.5 mL TID for prophylaxis and 20:1 vapor pen for acute pain. Together these products cost an average of $242 per month. (5) 15% of patients reported side effects, all minimal, with 63% related to administration route (poor taste, cough). No patients discontinued MC due to side effects.

Conclusions These results support MC as an option for treatment of concussion-related chronic pain. While prospective studies are required, these preliminary results lay the foundation for investigating MC as a valid treatment for concussion and chronic pain.

Footnotes

  • Disclosures: Dr. McVige has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Avinir, Teva, and Supernus. Dr. Bargnes has nothing to disclose. Dr. Shukri has nothing to disclose. Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Promius, Allergan, Avanir, Amgen.

  • © 2018 American Academy of Neurology

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise